-
EP3277720
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3277720
| EP3277720 - ANTI-CD303 MONOCLONAL ANTIBODIES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 18.02.2022 Database last updated on 21.03.2026 | |
| Former | Grant of patent is intended Status updated on 31.05.2021 | ||
| Former | Examination is in progress Status updated on 07.06.2019 | ||
| Former | Request for examination was made Status updated on 05.01.2018 | ||
| Former | The international publication has been made Status updated on 08.11.2016 | Most recent event Tooltip | 18.02.2022 | Application deemed to be withdrawn | published on 23.03.2022 [2022/12] | Applicant(s) | For all designated states Laboratoire Français du Fractionnement et des Biotechnologies Zone d'Activité de Courtaboeuf 3, avenue des Tropiques 91940 Les Ulis / FR | [2018/06] | Inventor(s) | 01 /
FOURNIER, Nathalie 20 impasse du Château d'eau La porte des Anglais 59193 Erquinghem-Lys / FR | 02 /
FONTAYNE, Alexandre 20 rue de l'abbé Lemire 59110 La Madeleine / FR | 03 /
DE ROMEUF, Christophe 14 avenue de l'Amiral Courbet 59130 Lambersart / FR | [2018/06] | Representative(s) | Regimbeau 20, rue de Chazelles 75847 Paris Cedex 17 / FR | [2018/06] | Application number, filing date | 16712886.7 | 31.03.2016 | [2018/06] | WO2016EP56995 | Priority number, date | FR20150052757 | 31.03.2015 Original published format: FR 1552757 | [2018/06] | Filing language | FR | Procedural language | FR | Publication | Type: | A1 Application with search report | No.: | WO2016156450 | Date: | 06.10.2016 | Language: | FR | [2016/40] | Type: | A1 Application with search report | No.: | EP3277720 | Date: | 07.02.2018 | Language: | FR | The application published by WIPO in one of the EPO official languages on 06.10.2016 takes the place of the publication of the European patent application. | [2018/06] | Search report(s) | International search report - published on: | EP | 06.10.2016 | Classification | IPC: | C07K16/28 | [2018/06] | CPC: |
C07K16/2851 (EP,CN,KR,US);
A61P29/00 (EP);
A61P35/00 (EP);
A61P37/00 (EP);
A61P37/06 (EP);
C12N15/79 (EP,US);
C07K2317/14 (US);
C07K2317/24 (EP,CN,KR,US);
C07K2317/52 (US);
C07K2317/54 (US);
C07K2317/55 (US);
C07K2317/56 (US);
C07K2317/565 (US);
C07K2317/567 (EP,CN,KR,US);
C07K2317/622 (US);
C07K2317/732 (EP,CN,KR,US);
C07K2317/734 (EP,CN,KR,US);
C07K2317/76 (EP,CN,KR,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2018/06] | Title | German: | MONOKLONALE ANTI-CD303-ANTIKÖRPER | [2018/06] | English: | ANTI-CD303 MONOCLONAL ANTIBODIES | [2018/06] | French: | ANTICORPS MONOCLONAUX ANTI-CD303 | [2018/06] | Entry into regional phase | 19.10.2017 | National basic fee paid | 19.10.2017 | Designation fee(s) paid | 19.10.2017 | Examination fee paid | Examination procedure | 19.10.2017 | Examination requested [2018/06] | 19.10.2017 | Date on which the examining division has become responsible | 09.05.2018 | Amendment by applicant (claims and/or description) | 27.03.2019 | Observations by third parties | 13.06.2019 | Despatch of a communication from the examining division (Time limit: M06) | 09.12.2019 | Reply to a communication from the examining division | 01.04.2020 | Despatch of a communication from the examining division (Time limit: M02) | 28.04.2020 | Reply to a communication from the examining division | 09.07.2020 | Despatch of a communication from the examining division (Time limit: M06) | 08.01.2021 | Reply to a communication from the examining division | 01.06.2021 | Communication of intention to grant the patent | 12.10.2021 | Application deemed to be withdrawn, date of legal effect [2022/12] | 04.11.2021 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2022/12] | Fees paid | Renewal fee | 23.03.2018 | Renewal fee patent year 03 | 22.03.2019 | Renewal fee patent year 04 | 20.03.2020 | Renewal fee patent year 05 | 23.03.2021 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [Y] WO2014093396 (BIOGEN IDEC INC et al.) | [Y] WO0136487 (MILTENYI BIOTECH GMBH et al.) | [Y] WO2012080642 (LFB BIOTECHNOLOGIES et al.) | [YA] EP2537864 (LFB BIOTECHNOLOGIES et al.) | [Y] WO2015098813 (ASTELLAS PHARMA INC et al.) [Y] 1-30 * page 67, paragraph 2; example -; claim - * * page 75, paragraph 3 - page 78, paragraph 4 * | [Y] JAHN P S ET AL: "BDCA-2 signaling inhibits TLR-9-agonist-induced plasmacytoid dendritic cell activation and antigen presentation", CELLULAR IMMUNOLOGY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 265, no. 1, 1 January 2010 (2010-01-01), pages 15 - 22, XP027236570, ISSN: 0008-8749, [retrieved on 20100706] | [Y] DZIONEK A ET AL: "BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, vol. 194, no. 12, 17 December 2001 (2001-12-17), pages 1823 - 1834, XP002277387, ISSN: 0022-1007, DOI: 10.1084/JEM.194.12.1823 DOI: http://dx.doi.org/10.1084/jem.194.12.1823 | [Y] CELINE MONNET ET AL: "Selection of IgG variants with increased FcRn binding using random and directed mutagenesis: impact on effector functions", FRONTIERS IN IMMUNOLOGY, vol. 6, no. 39, 4 February 2015 (2015-02-04), pages 1 - 14, XP055238838, DOI: 10.3389/fimmu.2015.00039 DOI: http://dx.doi.org/10.3389/fimmu.2015.00039 | [A] NAOKO YAMANE-OHNUKI ET AL: "Production of therapeutic antibodies with controlled fucosylation", MABS, LANDES BIOSCIENCE, US, vol. 1, no. 3, 1 May 2009 (2009-05-01), pages 230 - 236, XP002731447, ISSN: 1942-0862 DOI: http://dx.doi.org/10.4161/mabs.1.3.8328 | Examination | US2018086834 | US2018066060 | MAEDA TAKAHIRO ET AL: "A Novel Plasmacytoid Dendritic Cell Line, CAL-1, Established from a Patient with Blastic Natural Killer Cell Lymphoma", INTERNATIONAL JOURNAL OF HEMATOLOGY, ELSEVIER SCIENCE PUBLISHERS, NL, vol. 81, no. 2, 1 February 2005 (2005-02-01), pages 148 - 154, XP036522530, ISSN: 0925-5710, [retrieved on 20050201], DOI: 10.1532/IJH97.04116 DOI: http://dx.doi.org/10.1532/IJH97.04116 | A. PELLERIN ET AL: "Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms", EMBO MOLECULAR MEDICINE, vol. 7, no. 4, 1 April 2015 (2015-04-01), pages 464 - 476, ISSN: 1757-4676, DOI: 10.15252/emmm.201404719 [P] | DZIONEK A ET AL: "BDCA-2, BDCA-3, AND BDCA-4: THREE MARKERS FOR DISTINCT SUBSETS OF DENDRITIC CELLS IN HUMAN PERIPHERAL BLOOD", IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 165, no. 11, 1 December 2000 (2000-12-01), pages 6037 - 6046, XP000986292, ISSN: 0019-2805 | other | WO2012080642 | EP2651978 | US2013315820 | US2018066060 | US2018086834 | EP3277720 | MAEDA T. ET AL: "A Novel Plasmacytoid Dendritic Cell Line, CAL-1, Established from a Patient with Blastic Natural Killer Cell Lymphoma", INTERNATIONAL JOURNAL OF HEMATOLOGY, vol. 81, no. 2, 16 January 2018 (2018-01-16), pages 148 - 154, XP036411598 DOI: http://dx.doi.org/10.1532/IJH97.04116 | DZIONEK A. ET AL: "BDCA-2, BDCA-3, AND BDCA-4: THREE MARKERS FOR DISTINCT SUBSETS OF DENDRITIC CELLS IN HUMAN PERIPHERAL BLOOD", IMMUNOLOGY, vol. 165, no. 11, December 2000 (2000-12-01), pages 6037 - 6046, XP000986292 |